Table 2.

Ongoing Trials of Radiosensitizers

	Intervention			Study Population	No.	Estimated Start Date	Estimated Completion	Location
1	Lapatinib	NCT01591577	Dual tyrosine kinase inhibitor that interrupts the HER2/neu and epidermal growth factor receptor pathways	Newly diagnosed glioblastoma multiforme or gliosarcoma	70	December 7, 2012	December 7, 2019	Jonsson Comprehensive Cancer Center
2	ABI-009	NCT03463265	Nanoparticle albumin- bound rapamycin	Recurrent high- grade glioma and newly diagnosed glioblastoma	56	August 1, 2018	June 2021	John Wayne Cancer Institute

Abbreviations: ABI-009, nab-rapamycin; NCT, national clinical trial.